Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals. The U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, sprays, and sterile injectables, as well as products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The U.S. Branded Pharmaceuticals segment provides XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's diseases; SUPPRELIN LA for central precocious puberty treatment; TESTOPEL, a long-acting implantable pellet for the treatment of central precocious puberty; NASCOBAL, a nasal spray to treat vitamin B12 deficiency; and AVEED for the treatment of hypogonadism. This segment also offers pain management products, such as PERCOCET, VOLTAREN Gel, and LIDODERM; TESTIM Gel for the treatment of endogenous testosterone; and FORTESTA Gel for hypogonadism treatment. The International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. It sells its branded pharmaceuticals and generics directly to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ENDP
CUSIP29264F20
Phone011-353-1268-2000
Debt
Debt-to-Equity Ratio-1,161.84
Current Ratio1.06
Quick Ratio0.88
Price-To-Earnings
Trailing P/E Ratio2.84
Forward P/E Ratio4.02
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.47 billion
Price / Sales0.61
Cash Flow$8.5405 per share
Price / Cash1.11
Book Value$2.17 per share
Price / Book4.37
Profitability
EPS (Most Recent Fiscal Year)$3.84
Net Income$-2,035,430,000.00
Net Margins-75.58%
Return on Equity143.46%
Return on Assets6.30%
Miscellaneous
Employees3,039
Outstanding Shares223,790,000
Endo International (NASDAQ:ENDP) Frequently Asked Questions
What is Endo International's stock symbol?
Endo International trades on the NASDAQ under the ticker symbol "ENDP."
How were Endo International's earnings last quarter?
Endo International PLC (NASDAQ:ENDP) released its quarterly earnings results on Tuesday, May, 8th. The company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.55 by $0.12. The company had revenue of $700.53 million for the quarter, compared to analysts' expectations of $691.94 million. Endo International had a positive return on equity of 143.46% and a negative net margin of 75.58%. The firm's revenue was down 32.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.23 earnings per share. View Endo International's Earnings History.
When is Endo International's next earnings date?
What guidance has Endo International issued on next quarter's earnings?
Endo International updated its FY18 earnings guidance on Tuesday, May, 8th. The company provided EPS guidance of $2.15-2.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.34. The company issued revenue guidance of $2.6-2.8 billion, compared to the consensus revenue estimate of $2.74 billion.
What price target have analysts set for ENDP?
18 Wall Street analysts have issued 12-month target prices for Endo International's shares. Their predictions range from $7.00 to $16.00. On average, they expect Endo International's stock price to reach $8.8333 in the next year. View Analyst Ratings for Endo International.
What are Wall Street analysts saying about Endo International stock?
Here are some recent quotes from research analysts about Endo International stock:
- 1. According to Zacks Investment Research, "Endo’s guidance for 2018 was way below expectations. The generics business is under tremendous pressure due to the loss of marketing exclusivity for the first-to-file products ezetimibe tablets and quetiapine ER tablets in the first half of 2017. The branded pharmaceuticals business was impacted by continued generic competition for established products, product divestitures and ceasing shipments of Opana ER and this is expected to continue further. Endo withdrew opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market following FDA’s request in June 2017. The company divested its non-core assets such as Belbuca and restructured its pain franchise to focus particularly on specialty branded business. However, we expect challenging business conditions for the company in 2018. Shares have underperformed the industry over a year." (5/1/2018)
- 2. Cantor Fitzgerald analysts commented, "Takeaways from the quarter: 1) Executing well against its stated objectives in U.S. generics, during 4Q17, the U.S. generics segment launched six products and submitted two regulatory filings. In 2017, the U.S. generics segment launched 17 products and ENDP made 12 regulatory submissions. As of 12/31/17, ENDP had ~100 ANDAs (~1/3 FTF/FTM) pending with the FDA. 2) Sterile Injectables is a growing franchise. Sterile Injectables revenue increased 16% YOY. This increase was driven by Adrenalin. 3) Important sterile injectable drugs include Vasostrict and Adrenalin. ENDP reported 2017 Vasostrict sales of $400MM and Adrenalin sales of $77MM. 4) As of 12/31/17, ENDP had $987MM in unrestricted cash, net debt of ~$7.3B and a net leverage ratio of 4.6x. 5) 4Q17 cash provided by operating activities was $132MM, compared to $84MM of net cash provided by operating activities in 2016. 6) Cellulite could be a big opportunity for ENDP. RELEASE-1 And RELEASE-2 Phase 3 trials looking at Xiaflex for the treatment cellulite were initiated. Topline data are expected 1Q19. ENDP plans to submit all the data in 2019. ENDP expects to commercialize the product on its own, but would consider strategic alternatives. 7) ENDP thinks that the generic market seems more stable, but it is still early in 2018." (2/27/2018)
- 3. Mizuho analysts commented, "We Lower PT to $12 from $14; Buy on Valuation Rating Buy Previous Rating No Change Price (1/02) $8.10 Price Target $12.00 Previous Price Target $14.00 Summary We reiterate our Buy rating but lower our PT to $12 from $14. We think 2018 guidance may prove disappointing, but we continue to view the stock as undervalued." (1/3/2018)
Are investors shorting Endo International?
Endo International saw a increase in short interest during the month of May. As of May 31st, there was short interest totalling 37,589,907 shares, an increase of 13.6% from the May 15th total of 33,085,913 shares. Based on an average daily trading volume, of 3,983,471 shares, the days-to-cover ratio is presently 9.4 days. Approximately 18.8% of the shares of the stock are short sold. View Endo International's Current Options Chain.
Who are some of Endo International's key competitors?
Some companies that are related to Endo International include SAGE Therapeutics (SAGE), Alkermes (ALKS), Dr.Reddy's Laboratories (RDY), Agios Pharmaceuticals (AGIO), Catalent (CTLT), Loxo Oncology (LOXO), FibroGen (FGEN), Ionis Pharmaceuticals (IONS), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), Taro Pharmaceutical Industries (TARO), Ligand Pharmaceuticals (LGND), GW Pharmaceuticals (GWPH), Array Biopharma (ARRY) and Ultragenyx Pharmaceutical (RARE).
Who are Endo International's key executives?
Endo International's management team includes the folowing people:
- Mr. Paul V. Campanelli, Pres, CEO & Director (Age 56)
- Mr. Blaise Coleman, Exec. VP & CFO (Age 44)
- Mr. Terrance J. Coughlin, Exec. VP & COO (Age 52)
- Mr. Matthew Joseph Maletta, Exec. VP & Chief Legal Officer (Age 46)
- Mr. Antonio R. Pera, Pres of Par Pharmaceutical (Age 61)
Has Endo International been receiving favorable news coverage?
Media coverage about ENDP stock has been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Endo International earned a daily sentiment score of 0.10 on Accern's scale. They also assigned media stories about the company an impact score of 45.90 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Endo International's major shareholders?
Endo International's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BNP Paribas Arbitrage SA (1.47%), Diamond Hill Capital Management Inc. (0.49%), New York State Common Retirement Fund (0.25%), Alps Advisors Inc. (0.20%), Schroder Investment Management Group (0.19%) and American International Group Inc. (0.18%). Company insiders that own Endo International stock include Blaise Coleman, Matthew Joseph Maletta, Nancy J Hutson, Paul Campanelli, Roger H Kimmel and Terrance J Coughlin. View Institutional Ownership Trends for Endo International.
Which institutional investors are selling Endo International stock?
ENDP stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., New York State Common Retirement Fund, Van ECK Associates Corp, New York State Teachers Retirement System, American International Group Inc., California State Teachers Retirement System, Rhumbline Advisers and Gamco Investors INC. ET AL. View Insider Buying and Selling for Endo International.
Which institutional investors are buying Endo International stock?
ENDP stock was purchased by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, Schroder Investment Management Group, Alps Advisors Inc., Diamond Hill Capital Management Inc., Systematic Financial Management LP, Flinton Capital Management LLC, Tyers Asset Management LLC and Riverhead Capital Management LLC. Company insiders that have bought Endo International stock in the last two years include Blaise Coleman, Matthew Joseph Maletta, Paul Campanelli and Terrance J Coughlin. View Insider Buying and Selling for Endo International.
How do I buy shares of Endo International?
Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Endo International's stock price today?
One share of ENDP stock can currently be purchased for approximately $9.48.
How big of a company is Endo International?
Endo International has a market capitalization of $2.08 billion and generates $3.47 billion in revenue each year. The company earns $-2,035,430,000.00 in net income (profit) each year or $3.84 on an earnings per share basis. Endo International employs 3,039 workers across the globe.
How can I contact Endo International?
Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected]
MarketBeat Community Rating for Endo International (ENDP)
MarketBeat's community ratings are surveys of what our community members think about Endo International and other stocks. Vote "Outperform" if you believe ENDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENDP will underperform the S&P 500 over the long term. You may vote once every thirty days.
